CN117615776A - 用于治疗肠神经病的组合疗法 - Google Patents

用于治疗肠神经病的组合疗法 Download PDF

Info

Publication number
CN117615776A
CN117615776A CN202280042396.9A CN202280042396A CN117615776A CN 117615776 A CN117615776 A CN 117615776A CN 202280042396 A CN202280042396 A CN 202280042396A CN 117615776 A CN117615776 A CN 117615776A
Authority
CN
China
Prior art keywords
combination
scfa
gdnf
pharmaceutically acceptable
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280042396.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·索雷特
N·皮隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus LP
Original Assignee
Transfert Plus LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus LP filed Critical Transfert Plus LP
Publication of CN117615776A publication Critical patent/CN117615776A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/124—Acids containing four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280042396.9A 2021-06-16 2022-06-15 用于治疗肠神经病的组合疗法 Pending CN117615776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202549P 2021-06-16 2021-06-16
US63/202,549 2021-06-16
PCT/CA2022/050955 WO2022261765A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Publications (1)

Publication Number Publication Date
CN117615776A true CN117615776A (zh) 2024-02-27

Family

ID=84526051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280042396.9A Pending CN117615776A (zh) 2021-06-16 2022-06-15 用于治疗肠神经病的组合疗法

Country Status (8)

Country Link
US (1) US20240366723A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523413A (cg-RX-API-DMAC7.html)
KR (1) KR20240021837A (cg-RX-API-DMAC7.html)
CN (1) CN117615776A (cg-RX-API-DMAC7.html)
AU (1) AU2022294711A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261765A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110440A1 (en) * 2013-01-10 2014-07-17 Biogen Idec Ma Inc. Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Also Published As

Publication number Publication date
EP4355354A4 (en) 2025-04-09
WO2022261765A1 (en) 2022-12-22
JP2024523413A (ja) 2024-06-28
AU2022294711A1 (en) 2023-12-21
US20240366723A1 (en) 2024-11-07
CA3220781A1 (en) 2022-12-22
EP4355354A1 (en) 2024-04-24
KR20240021837A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
US8399408B2 (en) Method for treating diabetes using neurturin
Sandvig et al. Myelin‐, reactive glia‐, and scar‐derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration
US8796199B2 (en) Uses of Cerberus and derivatives thereof
AU2001233502B2 (en) Pancreatic islet cell growth factors
CN109715191A (zh) 将赘生性细胞转化成非赘生性细胞的药物缔合物及其用途
US20100130574A1 (en) Neurodegenerative diseases and methods of modeling
CN117615776A (zh) 用于治疗肠神经病的组合疗法
CN109715190A (zh) 将赘生性细胞转化成非赘生性细胞的生长因子受体激动剂和黏附蛋白抑制剂的药物缔合物及其用途
JP2002512627A (ja) Ｃｎｓ神経再生組成物及びその使用方法
EP4076499B1 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
US20080089868A1 (en) Retinal stem cell compositions and methods for preparing and using same
WO2015133459A1 (ja) 角膜疾患若しくは角膜損傷の予防、抑制又は治療剤、細胞シート、細胞培養補助剤、並びに細胞培養方法
US20070110728A1 (en) Method for preventing and treating diabetes using dg119
WO2018106982A1 (en) Compositions and methods for enhancing beta cell maturation, health and function
KR100409099B1 (ko) 신경 손상 치료 기구
WO2022046771A1 (en) Juvenile protective factors to arrest and reverse aging in the enteric nervous system
CN120501871A (zh) 调控bbs相关蛋白的试剂用于治疗纤毛病的用途
Mitrousis A Bioengineering Approach Towards Retina Regeneration
WO2015044379A1 (en) A dyrk1a polypeptide for use in preventing or treating metabolic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination